PharmaLex Group has completed the merger with BioStat Solutions, Inc. (BSSI).
Founded in 2001 by Ena and Ron Bromley, BSSI provides analytical expertise in clinical, bioinformatics and translational medicine research including the design, analysis, and interpretation of complex data to pharmaceutical and biotechnology companies. Based in Frederick, Maryland, US, BSSI proactively identifies and provides analytical solutions to resolve data complexities inherent to pharmaceutical and biotech industries with their ever increasing heterogeniety, volume and complexity of data. BSSI supports clients with biostatistical and bioinformatic analysis and provides assistance in navigating the landscape of high-dimensional data, including real world evidence and -omics data.
Following the merger with PharmaLex, Dr. Lin Li will take over management of BSSI. Ron Bromley will step down as CEO, while Dr. Ena Bromley will continue to provide support as non-executive director and principal consultant.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!
“PharmaLex is a leading service provider in the pharma, biotech and medical device industries”, explained Lin Li, Senior Director of Scientific Operations, BioStat Solutions. “It is an exciting challenge to support them in developing their statistical solutions services and I look forward to leading the US team”, he added.
“BSSI has provided a standard of excellence in the industry”, Dr. Bruno Boulanger, Chief Scientific Officer, PharmaLex said. “We are very excited about this collaboration and the new possibilities it presents for our existing statistical services.”
“BSSI has had a focus on translational medicine and bioinformatics”, Dr. Thomas Dobmeyer, CEO PharmaLex said. “Their service portfolio complements nicely with our existing statistical solutions which focuses more on Bayesian statistics and will allow us to further enhance the services we are able to offer our clients – within the growing biomarker and bioinformatics market, which are both expected to grow with >13% per annum.”